Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy. Dermatology Reports, [S. l.], 2025. DOI: 10.4081/dr.2025.10315. Disponível em: https://journals.pagepress.org/dr/article/view/10315. Acesso em: 4 aug. 2025.